[Generalised toxicoderma secondary to administering liposomal amphotericin B].
de Miguel-Bouzas
J C
JC
Herrero-Poch
L
L
Piñeiro-Corrales
G
G
D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D017544:Aortic Aneurysm, Abdominal / Q000150:complications / Q000175:diagnosis / Q000601:surgery; D002177:Candidiasis / Q000188:drug therapy; D002280:Basal Cell Carcinoma / Q000150:complications / Q000601:surgery; D003875:Drug Eruptions / Q000209:etiology*; D004359:Drug Therapy, Combination; D006801:Humans; D033162:Incidental Findings; D008081:Liposomes; D008297:Male; D009669:Nose Neoplasms / Q000150:complications / Q000601:surgery; D011183:Postoperative Complications / Q000188:drug therapy; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced*
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D008081:Liposomes; C068538:liposomal amphotericin B; D000666:Amphotericin B